BioStock: Lipum looks ahead to phase II with backing from Flerie

Lipum has finalised the clinical study report for its phase I trial of the drug candidate SOL-116, officially concluding the study. The company’s largest shareholder, Flerie, played a key role in supporting the execution of the trial. To gain further insight, we spoke with Karl Elmqvist, Investment Manager at Flerie, and Ola Sandborgh, CEO of Lipum.
– The phase I results give us strong confidence as SOL-116 progresses to the next stage of development, says Karl Elmqvist.

Read the full article at biostock.se:

https://www.biostock.se/en/2025/04/lipum-looks-ahead-to-phase-ii-with-backing-from-flerie/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se